DZANK1 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for the disruption of the DZANK1 gene in the HAP1 cell background. This product delivers a heterogeneous population of knockout cells, each carrying distinct loss-of-function mutations introduced by non-homologous end joining, providing a versatile tool for studying DZANK1-dependent processes without the need for clonal isolation. The polyclonal format preserves genetic diversity while ensuring robust target gene inactivation across the population, enabling consistent phenotypic analysis in bulk assays. These cells are supplied as a ready-to-use resource for researchers investigating centrosome biology, cilia function, and associated signal transduction networks.
The host cell line HAP1 is a human near-haploid chronic myeloid leukemia cell line derived from a male patient, characterized by a stable near-haploid karyotype. This unique genetic configuration eliminates diploid redundancy, making HAP1 an ideal model for genetic knockout studies, as a single mutation can produce a complete loss-of-function phenotype. The near-haploid nature simplifies genotype?Cphenotype correlations and is particularly advantageous for dissecting the roles of genes involved in complex biological processes such as cell signaling and ciliogenesis. HAP1 cells are widely adopted in functional genomics, high-content screening, and CRISPR-Cas9-mediated gene editing due to their robust growth and ease of manipulation.
DZANK1 encodes a centrosomal protein featuring ankyrin repeat and zinc ribbon domains, which localizes to the centrosome and basal body and is essential for primary cilium assembly and ciliary signal transduction. Mechanistically, DZANK1 is regulated by upstream factors including the RFX family of transcription factors and FOXJ1, as well as mitotic kinases such as PLK1 and Aurora A, which coordinate its centrosomal functions. DZANK1 interacts directly with core centrosomal and ciliary components like PCM1, CEP290, BBSome proteins, and tubulin, forming scaffold complexes critical for ciliogenesis. Its downstream effects are mediated through modulation of Hedgehog signaling ?? controlling the processing and activation of GLI transcription factors downstream of the SHH?CPTCH1?CSMO axis ?? and Wnt signaling, where it influences ??-catenin stability and TCF/LEF-mediated transcription. Ciliary trafficking proteins such as IFT88 and the small GTPase ARL13B also depend on DZANK1 for proper localization and function. Disruption of DZANK1 leads to defective cilium structure, impaired Hedgehog pathway activation, and attenuated Wnt responses.
In the HAP1 model, DZANK1 knockout exploits the haploid background to unmask phenotypic consequences of gene loss, facilitating clear interpretation of ciliary defects and signaling alterations. The lack of a second allele reduces compensatory effects, making this system particularly sensitive for identifying DZANK1??s role in ciliogenesis and its intersection with cytoskeletal organization. This model is relevant for studying ciliopathy-related conditions such as syndromic retinal dystrophy, obesity, and Bardet?CBiedl syndrome, where primary cilia dysfunction is a central pathological mechanism. The combination of HAP1??s tractability with DZANK1 knockout enables rigorous, reproducible investigations into centrosome-dependent signal integration.
Research applications for these polyclonal knockout cells include detailed mechanistic studies of ciliogenesis, quantitative analysis of Hedgehog and Wnt signaling pathways, and disease modeling of ciliopathies. Typical experimental workflows involve immunofluorescence microscopy for ciliary markers such as acetylated tubulin and ARL13B to assess cilia formation and morphology; western blotting of Hedgehog pathway components (GLI proteins, PTCH1) or ??-catenin levels; RT-qPCR to measure pathway target gene expression; ciliogenesis assays under serum starvation; and co-immunoprecipitation to probe DZANK1-containing protein complexes. These cells are also suitable for drug screening campaigns aimed at identifying modulators of retinal dystrophy or other cilia-related disorders. For inquiries regarding this product, please contact Ascent Research.
